Hypo/Hyperkalemia Management & Disposition

---

Overview & ECG Progression

Potassium disorders are common ED presentations with significant morbidity if missed. Both hypo- and hyperkalemia can cause life-threatening dysrhythmias, but the clinical threshold for intervention differs markedly. Hypokalemia often requires admission and careful repletion, while hyperkalemia with ECG changes represents a medical emergency requiring immediate treatment.

ECG Changes by Potassium Level

Potassium Level	Hypokalemia ECG Changes	Hyperkalemia ECG Changes
Mild 3.0-3.5 (hypo) 5.5-6.0 (hyper)	ST segment depression, T wave flattening, U waves prominent	Peaked T waves (typically symmetric)
Moderate 2.5-3.0 (hypo) 6.0-7.0 (hyper)	Prominent U waves, prolonged PR interval, widened QRS	Peaked T waves, PR prolongation, QRS widening begins
Severe <2.5 (hypo) >7.0 (hyper)	Atrial fibrillation, AV block, ventricular dysrhythmias	Severe QRS widening, loss of P waves, ST elevation, sine wave pattern, asystole risk

---

Hypokalemia Templates

Mild Hypokalemia (3.0-3.5 mEq/L)

Moderate Hypokalemia (2.5-3.0 mEq/L)

Severe Hypokalemia (<2.5 mEq/L)

---

Hyperkalemia Templates

Mild Hyperkalemia (5.5-6.0 mEq/L, no ECG changes)

Moderate Hyperkalemia (6.0-7.0 mEq/L, with peaked T waves)

Severe Hyperkalemia (>7.0 mEq/L or >6.0 with severe ECG changes)

---

ECG Changes in Detail

Hypokalemia ECG Progression

• ST Segment Depression: Occurs early, becomes more pronounced as K+ falls
• T Wave Flattening/Inversion: Especially in lateral leads (II, III, aVF, V5-V6)
• U Waves: Become increasingly prominent, may exceed T wave amplitude
• PR Interval Prolongation: Can occur at moderate levels
• QRS Widening: In severe hypokalemia
• Atrial Fibrillation: Can develop suddenly, especially if concurrent hypomagnesemia

Hyperkalemia ECG Progression

• Peaked T Waves: The earliest and most sensitive finding. Typically symmetric and narrow-based, maximal in precordial leads. Appear when K+ >5.5 mEq/L
• PR Interval Prolongation: Slowed AV conduction, can progress to AV block
• QRS Widening: Progressive widening as K+ rises, loss of S waves
• Loss of P Waves: Indicates severe hyperkalemia, can progress to sine wave pattern
• ST Elevation: May mimic STEMI pattern
• Sine Wave Pattern: Ominous finding indicating imminent cardiac arrest if untreated

---

Potassium Repletion

Oral Potassium Supplementation

• Indications: Mild hypokalemia, stable patients who can tolerate PO
• Formulations:
  • KCl liquid: 20 mEq/15 mL (tastes bad, often used for rapid repletion)
  • KCl tablets: 20-25 mEq per tablet
  • Potassium-containing foods: bananas, oranges, tomatoes, spinach, potatoes (1 medium banana ~10 mEq)
• Dosing: 20-40 mEq daily in divided doses for mild-moderate deficiency; can increase to 60-80 mEq/day for rapid repletion but monitor GI tolerance
• Monitoring: Serum K+ 24-48 hours after initiation, then as clinically indicated
• Cautions: GI upset common (especially liquid formulation); take with food; hyperkalemia risk if renal impairment or concurrent medications that reduce urinary K+ excretion

Intravenous Potassium Supplementation

• Indications: Moderate-severe hypokalemia, symptomatic patients, unable to take PO, cardiac dysrhythmias
• Peripheral IV (Max concentration 40 mEq/L in 100 mL, max rate 10 mEq/hour):
  • 10-20 mEq in 100 mL NS over 1-2 hours
  • Monitor for irritation and extravasation (potassium is caustic)
  • Repeat as needed based on serum K+ and clinical response
• Central IV (Max concentration 80 mEq/L, max rate 20 mEq/hour):
  • 20-40 mEq in 50-100 mL NS over 1-2 hours
  • Better for rapid repletion and higher doses
  • Preferred for ICU patients requiring close monitoring
• Monitoring: Continuous cardiac monitoring during repletion; repeat serum K+ Q2-4H initially; watch for hyperkalemia (peaked T waves, widened QRS)
• Cautions: Hyperkalemia risk (especially with renal dysfunction); risk of hypomagnesemia not improving K+ levels; pain at infusion site

Magnesium and Calcium Considerations

• Hypomagnesemia: Present in ~50% of hypokalemia cases and prevents effective K+ repletion. Must be corrected (goal Mg2+ >2 mg/dL) for K+ repletion to be effective
• Replacement: Magnesium sulfate 1-2 g IV or PO magnesium oxide 400 mg daily
• Hypocalcemia: Concurrent hypocalcemia (from hypomagnesemia or other causes) should be repleted; calcium stabilizes cardiac membrane and reduces dysrhythmia risk

---

Hyperkalemia Treatment Ladder

Step 1: Cardioprotection (Urgent for ECG changes)

• Calcium Gluconate 10% or Calcium Chloride 10%: Stabilizes cardiac membrane; does NOT lower K+ but reduces dysrhythmia risk
  • Calcium Gluconate: 10 mL of 10% solution (1 gram) IV push over 2-5 minutes
  • Calcium Chloride: 5-10 mL of 10% solution (500-1000 mg) IV push over 2-5 minutes (more irritating to veins, use central line if possible)
  • Effect: Immediate (within 1-3 minutes), duration ~30-60 minutes
  • Can repeat in 5 minutes if ECG remains abnormal
  • Check calcium level; hyperkalemia treatment should not cause hypercalcemia

Step 2: Shift K+ Intracellularly (Within 15-30 minutes)

• Regular Insulin + Dextrose: Most effective K+ lowering agent
  • Insulin 10 units IV with D50W 25 grams (50 mL of 50% solution) OR D10W 250 mL
  • Effect: 0.5-1.2 mEq/L reduction in 15-30 minutes, duration 4-6 hours
  • Monitor blood glucose; risk of hypoglycemia
  • Avoid in hypoglycemia; check baseline glucose first
• Beta-2 Agonists: Albuterol increases cellular K+ uptake
  • Albuterol 10-20 mg nebulized (or 0.5 mg IV)
  • Effect: 0.5-1.0 mEq/L reduction in 30 minutes, duration 2-4 hours
  • Tachycardia and tremor common side effects
  • Less effective than insulin but useful adjunct, especially in combo
  • Relative contraindication: symptomatic coronary artery disease, uncontrolled hypertension, arrhythmias

Step 3: Increase Renal Excretion (Takes 4-24 hours)

• Loop Diuretics (Furosemide, Bumetanide, Torsemide): If adequate renal function and euvolemia/hypervolemia
  • Furosemide 40-80 mg IV or higher if needed
  • Effect: 0.3-0.5 mEq/L reduction per liter of urine output (gradual)
  • Monitor urine output and electrolytes
  • Ineffective in acute kidney injury or renal failure
• Cation Exchange Resins (Sodium Polystyrene Sulfonate – SPS/Kayexalate, Patiromer, Sodium Zirconium Cyclosilicate):
  • SPS: 15-60 g PO/PR, onset 2-12 hours, duration 4-24 hours (can cause constipation or diarrhea; increasingly controversial due to GI necrosis risk)
  • Patiromer: 8.4-25.2 g daily, onset 7 hours, lasts up to 48 hours (newer agent, better tolerated)
  • Sodium Zirconium Cyclosilicate: 10 g three times daily, rapid onset (within 1 hour), lasts 24-48 hours (preferred newer agent)

Step 4: Dialysis (For refractory or severe cases)

• Indications: Acute kidney injury with hyperkalemia, severe renal failure (CKD stage 5), failure to respond to medical management, life-threatening ECG changes unresponsive to calcium/insulin
• Hemodialysis: Rapidly removes K+; effect seen within minutes to hours; can remove 25-50 mEq per session
• Continuous Renal Replacement Therapy (CRRT): For hemodynamically unstable patients

Sample Treatment Regimens by Severity

• Mild (5.5-6.0, no ECG changes): Address underlying cause, dietary restriction, repeat K+ in 24-48 hours
• Moderate (6.0-7.0, peaked T waves): Calcium 10 mL IV (cardioprotection), Insulin 10 units + D50W (K+ shift), Furosemide 40 mg IV, Patiromer or Sodium Zirconium Cyclosilicate, Repeat K+ Q2-4H
• Severe (>7.0 or severe ECG changes): Calcium 10 mL IV (repeat if needed), Insulin 10 units + D50W, Albuterol 10-20 mg neb, Furosemide 80-120 mg IV, Consider Dialysis, Continuous monitoring, Repeat K+ Q1-2H

---

Spurious Hyperkalemia & Hemolysis Correction

Spurious hyperkalemia occurs in ~5-10% of cases with drawn hyperkalemia and is due to in vitro hemolysis during phlebotomy, processing, or lab handling rather than true serum K+ elevation. Critical to recognize to avoid unnecessary treatment.

Causes of Spurious Hyperkalemia

• Hemolysis during phlebotomy: Difficult draw, small gauge needle, prolonged tourniquet application, vigorous tube mixing
• Prolonged sample storage: K+ leaks from RBCs if sample sits at room temperature
• Lab processing errors: Improper centrifugation, delayed processing
• Leukocytosis or thrombocytosis: Large numbers of WBCs/platelets can falsely elevate K+ (especially in CLL, acute leukemia, severe thrombocytosis)

How to Recognize and Correct for Spurious Hyperkalemia

• Visual inspection: Look for hemolysis – pink/red discoloration of serum (vs pale straw color in normal)
• Check LDH and haptoglobin: Elevated LDH (>normal) and low haptoglobin suggest hemolysis
• Compare with plasma K+: If plasma K+ is normal but serum K+ is high, suggests hemolysis artifact
• Clinical correlation: Asymptomatic patient with “hyperkalemia” + normal ECG = likely spurious
• Redraw sample: If spurious suspected, redraw (careful technique) and send stat; likely to be normal
• Correction formula: If hemolysis confirmed and significant:
  • If WBC <100 x 10⁹/L and platelets <1000 x 10⁹/L: Assume artifact is mainly from hemolysis
  • Correct K+ = Measured K+ – (LDH_serum – LDH_normal) × correction factor (typically 0.002-0.006 depending on lab)
  • Simpler approach: redraw with better technique rather than trying to calculate correction

Management of Confirmed Spurious Hyperkalemia

• Do NOT treat the hyperkalemia
• Obtain properly drawn repeat sample for true K+ level
• Reassure patient (if spurious is confirmed)
• Document hemolysis in chart
• Educate patient about the importance of repeat testing

---

Digoxin Toxicity

Hyperkalemia significantly increases risk and severity of digoxin toxicity. Both potassium and digitalis compete for Na+/K+-ATPase pump binding, and hyperkalemia exacerbates digitalis toxicity.

Mechanism of Interaction

• Elevated K+ directly inhibits Na+/K+-ATPase
• Digoxin also blocks this pump (therapeutic goal at lower doses)
• Combination can cause severe conduction abnormalities and dysrhythmias (AV block, bradycardia, ectopy)
• Risk significantly increased when K+ >5.5 mEq/L in patient on digoxin

Clinical Presentation

• Dysrhythmias: PACs, PVCs, junctional rhythms, AV blocks, bradycardia
• May have nausea, anorexia, visual changes (typical digoxin toxicity symptoms)
• ECG may show digoxin effect (sagging ST segment, “smile” sign) plus hyperkalemia changes (peaked T, widened QRS)

Management

• Treat hyperkalemia aggressively: Use full treatment ladder (calcium, insulin, albuterol, diuretics)
• Monitor digoxin levels: Check serum digoxin concentration if available (therapeutic 0.8-2 ng/mL; toxicity typically >2.5 ng/mL, but variable)
• Consider Digoxin-Specific Antibody Fragments (Digoxin Fab / DigiBind / DigiFab):
  • Indicated for severe toxicity with hemodynamic instability, high digoxin levels, or refractory dysrhythmias
  • Rapidly binds and inactivates digoxin
  • Standard dose: 10 vials IV if digoxin level unknown or severe toxicity; can repeat based on response
• Adjust or hold digoxin: Hold dose; may need to reduce long-term dose or discontinue depending on clinical scenario and renal function
• Avoid calcium channel blockers and beta-blockers if possible: Can worsen conduction abnormalities in context of hyperkalemia + digoxin
• Correct magnesium and calcium: Hypomagnesemia and hypocalcemia worsen digoxin toxicity; repleted as needed

---

Disposition Table

Condition	Disposition	Monitoring Level	Key Points
Hypokalemia 3.0-3.5 (asymptomatic, normal ECG)	Outpatient or observation	PO repletion; repeat K+ in 24-48h	Address etiology; counsel on dietary K+
Hypokalemia 2.5-3.0 (symptomatic or ECG changes)	Admission (floor with monitoring)	IV repletion; repeat K+ Q2-4H; cardiac monitoring	Correct concurrent Mg2+ deficiency; avoid over-correction
Hypokalemia <2.5	ICU admission	Continuous telemetry; central line IV repletion	High risk dysrhythmia; frequent labs; address Mg2+ and other electrolytes
Hyperkalemia 5.5-6.0 (no peaked T waves, normal ECG)	Outpatient or observation	Address underlying cause; dietary restriction; repeat K+ in 1-3 days	Rule out spurious hyperkalemia; check renal function
Hyperkalemia 6.0-7.0 (peaked T waves)	Admission (floor with monitoring)	Cardiac monitoring; treatment ladder; repeat K+ Q2-4H	Calcium, Insulin/Dextrose, Diuretics, Cation resins; address cause
Hyperkalemia >7.0 or severe ECG changes	ICU admission	Continuous telemetry; full treatment ladder; consider dialysis	Emergent treatment; repeat K+ Q1-2H; risk of cardiac arrest
Spurious Hyperkalemia (hemolysis confirmed)	No admission needed; redraw sample	None, if truly spurious	Do NOT treat; repeat K+ with careful technique; check LDH/haptoglobin
Hyperkalemia + Digoxin on board	Admission (ICU if severe)	Continuous monitoring; aggressive K+ lowering; consider Fab fragments	High risk for severe dysrhythmias; treat hypokalemia first if mixed

---

References

1. Diuretic use and hyperkalemia risk in ACE inhibitor/ARB treated patients
2. Electrocardiographic manifestations of hypokalemia
3. Hyperkalemia management and treatment algorithms
4. Insulin-dextrose therapy in acute hyperkalemia
5. ECG changes in severe hyperkalemia and risk of sudden cardiac death
6. Calcium gluconate vs calcium chloride in hyperkalemia management
7. Hypokalemia and magnesium depletion relationship
8. Spurious hyperkalemia: causes and correction factors
9. Digoxin toxicity and electrolyte interactions
10. Patiromer and sodium zirconium cyclosilicate as K+ binding agents

This MDM provides a framework for clinical decision-making. Potassium disorders require thoughtful evaluation of clinical context, ECG findings, renal function, and concurrent medications. Management should be individualized to each patient, and treatment decisions should balance risks and benefits. Always consult primary literature and institutional protocols for the most up-to-date recommendations. Treatment decisions should be individualized to each patient’s clinical context.